Metabolic Disease

Researchers showed that insulin resistance exists on a spectrum among diabetics and healthy controls. 

Explore the link between GLP-1 drugs and cancer. A new study reveals these therapies may reduce the risk of obesity-related cancers, similar to bariatric surgery.

Explore how the gut microbiome impacts health. Learn about a new study that reveals how a specific microbe, P. faecium, may help fight obesity.

A new compound, Vykat XR, addresses insatiable hunger in the rare genetic condition, offering relief for patients and hope for families.

A new method for tracking dietary intake used DNA in stool to detect nutritional content from a broad range of foods.

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.

GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.

Targeting a gut bacterial species or its metabolites could potentially improve diabetes management by reducing sugar preferences. 

Sagimet’s denifanstat delivered significant improvements in disease activity and fibrosis for patients with metabolic dysfunction-associated steatohepatitis.

Injectable micelles that release glucagon could provide a new way to treat hypoglycemic events in diabetes.

Customizable hydrogels could make taking diabetes and cancer medications as well as other biologics easier for patients.

AMSBIO has launched a glucagon-like peptide 1 receptor (GLP-1R) reporter cell line.